Ignite Creation Date:
2024-05-06 @ 12:54 AM
Last Modification Date:
2024-10-26 @ 10:56 AM
Study NCT ID:
NCT01683188
Status:
TERMINATED
Last Update Posted:
2021-02-01
First Post:
2012-09-07
Brief Title:
HD IL-2 Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Sponsor:
Clinigen Inc
Organization:
Clinigen Inc
Organization Data
Organization:
Clinigen Inc
Class:
INDUSTRY
Study ID:
12PLK01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Clinigen Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Prometheus Laboratories | INDUSTRY |